One Dose of Tranexamic Acid Is Safe and Effective in Revision Knee Arthroplasty

Revision total knee arthroplasty (TKA) has been associated with an increased risk of perioperative blood loss. Tranexamic acid (TXA) has been proven to be safe and effective in preventing blood loss in primary TKA. The purpose of this study was to evaluate the effect of TXA on blood loss and transfu...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of arthroplasty Vol. 28; no. 8; pp. 112 - 115
Main Authors: Smit, Kevin M., Naudie, Douglas D.R., Ralley, Fiona E., Berta, Donna M., Howard, James L.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01.09.2013
Subjects:
Aged
Antifibrinolytic Agents - adverse effects
Antifibrinolytic Agents - therapeutic use
Arthroplasty, Replacement, Knee
blood loss
Blood Loss, Surgical - prevention & control
Blood Transfusion - statistics & numerical data
Cohort Studies
Dose-Response Relationship, Drug
Female
Hemoglobins - metabolism
Humans
Male
Middle Aged
Orthopedics
Reoperation
Retrospective Studies
revision knee arthroplasty
tranexamic acid
Tranexamic Acid - adverse effects
Tranexamic Acid - therapeutic use
Treatment Outcome
blood loss
tranexamic acid
revision knee arthroplasty
ISSN:0883-5403, 1532-8406, 1532-8406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Revision total knee arthroplasty (TKA) has been associated with an increased risk of perioperative blood loss. Tranexamic acid (TXA) has been proven to be safe and effective in preventing blood loss in primary TKA. The purpose of this study was to evaluate the effect of TXA on blood loss and transfusion rates in revision TKA. We performed a retrospective comparative study on 424 patients who had undergone revision TKA between January 2006 and March 2010. A total of 178 patients did not receive TXA while 246 patients received one intraoperative dose of 20mg/kg of TXA given prior to tourniquet release. There was a significant reduction in hemoglobin loss (42±16g/L vs 38±15g/L, P=0.005), transfusion rates (30.3% vs 16.7%, P=0.001) and average amount transfused (1.1±1.9units vs 0.5±1.1units, P=0.001) in the TXA group. There was no significant difference in recorded major adverse events with the administration of TXA.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0883-5403
1532-8406
1532-8406
DOI:10.1016/j.arth.2013.05.036